Headlands Technologies LLC Invests $55,000 in Owens & Minor, Inc. (NYSE:OMI)

Headlands Technologies LLC bought a new position in shares of Owens & Minor, Inc. (NYSE:OMI) in the first quarter, HoldingsChannel reports. The institutional investor bought 6,132 shares of the company’s stock, valued at approximately $55,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in shares of Owens & Minor by 758.3% during the fourth quarter. Sterling Capital Management LLC now owns 2,060 shares of the company’s stock worth $27,000 after acquiring an additional 1,820 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Owens & Minor by 537.6% during the first quarter. Versant Capital Management Inc now owns 3,201 shares of the company’s stock worth $29,000 after acquiring an additional 2,699 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Owens & Minor by 1,387.0% during the first quarter. Parallel Advisors LLC now owns 3,316 shares of the company’s stock worth $30,000 after acquiring an additional 3,093 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Owens & Minor by 713.4% during the first quarter. GAMMA Investing LLC now owns 9,265 shares of the company’s stock worth $84,000 after acquiring an additional 8,126 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Owens & Minor during the first quarter worth $96,000. Institutional investors own 98.04% of the company’s stock.

Owens & Minor Stock Up 17.3%

Shares of Owens & Minor stock opened at $5.43 on Wednesday. The company has a quick ratio of 0.41, a current ratio of 0.86 and a debt-to-equity ratio of 3.32. Owens & Minor, Inc. has a 12 month low of $4.56 and a 12 month high of $16.63. The business has a fifty day simple moving average of $7.74 and a 200 day simple moving average of $8.04. The stock has a market cap of $419.39 million, a PE ratio of -0.35, a price-to-earnings-growth ratio of 0.20 and a beta of 1.04.

Owens & Minor (NYSE:OMI) last posted its earnings results on Monday, August 11th. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.01). Owens & Minor had a negative net margin of 13.78% and a positive return on equity of 26.59%. The business had revenue of $681.90 million during the quarter, compared to analyst estimates of $2.73 billion. During the same period in the previous year, the firm posted $0.36 earnings per share. The firm’s revenue was up 3.3% on a year-over-year basis. Research analysts predict that Owens & Minor, Inc. will post 1.51 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. set a $10.00 target price on Owens & Minor in a research report on Monday. Bank of America decreased their price objective on Owens & Minor from $7.50 to $4.75 and set an “underperform” rating for the company in a research note on Tuesday. Baird R W raised Owens & Minor from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 8th. UBS Group reaffirmed a “buy” rating on shares of Owens & Minor in a research note on Monday. Finally, Citigroup reaffirmed a “buy” rating and set a $7.00 price objective (down from $11.00) on shares of Owens & Minor in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.29.

Owens & Minor Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.